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Abstract
Background: Some oral hypoglycemic agents (OHAs) have been suggested to reduce the risk of cardiovascular disease
(CVD) in type-2 diabetes mellitus (T2DM). We ascertained if OHAs affect CVD risk in a cohort analysis of a multicenter
medical-cost accounting database in Japan.
Methods: Data of 4095 and 1273 T2DM patients in study 1 and study 2, respectively, were extracted from the database
based on the following conditions: (i) began treatment with a single OHA (sulfonylurea, biguanide, thiazolidinedione,
α-glucosidase inhibitor, glinide, or dipeptidyl peptidase-4 inhibitor) and continued the medication for ~1–1.4 years;
(ii) hemoglobin (Hb)A1c level at baseline was available; (iii) age at baseline was 40–70 years; (iv) presence or absence of
CVD history was not considered in study 1, but presence of CVD history was considered in study 2. Effects of OHAs
relative to sulfonylurea on CVD risk according to ICD-10 were analysed using Kaplan-Meier curves during 104 weeks.
Results: In study 1 targeting T2DM patients with and without a history of CVD, initial and baseline treatment with a
biguanide significantly lowered the risk of CVD compared with that with a sulfonylurea, and was independent of
HbA1c control. In study 2, a similar significant preventive effect of a biguanide on CVD risk relative to a sulfonylurea
was observed in T2DM patients with history of CVD.
Conclusions: Initial treatment and baseline treatment with a biguanide can reduce CVD risk relative to a sulfonylurea
independent of the blood glucose-lowering effect of the biguanide in Japanese T2DM patients.
Background
Subjects with diabetes mellitus (DM) carry a higher risk of
cardiovascular disease (CVD) than healthy individuals. A
total of 40.4 % of individuals with type-2 DM (T2DM) die
from CVD [1]. In an observational study in Finland, the
prevalence of myocardial infarction (MI) in T2DM patients
without a history of MI and in non-T2DM patients with a
history of MI was similar (20.2 and 18.8 %, respectively) [2].
In Japan, the relative risk of coronary heart disease or cere-
bral infarction has been reported to be 3.0 compared with
subjects with normal tolerance to glucose [3]. If MI occurs
in a patient with DM, the risk of future mortality can in-
crease by up to 4.6-fold compared with patients without
DM without a history of MI [4]. However, the risk of CVD
cannot be predicted completely by measuring levels of fast-
ing blood glucose or hemoglobin (Hb)A1c, which is usually
measured to observe the efficacy of anti-DM drugs for low-
ering glucose levels in blood. Several clinical trials have
attempted to examine the incidence of CVD as a feature of
drug efficacy [5–7].
Roumie et al. analyzed the efficacy of oral hypoglycemic
agents (OHAs) for the prevention of cardiovascular
events. They reported that metformin showed a significant
reduction in the prevalence of death compared with a sul-
fonylurea (SU) [5]. The Study to Prevent Non-Insulin
Dependent Diabetes Mellitus (STOP-NIDDM) revealed
that the incidence of cardiovascular events or hyperten-
sion was reduced significantly in patients using one type
of α-glucosidase inhibitor (α-GI): acarbose [7]. Meta-
analyses of seven clinical trials focusing on acarbose
showed similar results [8]. The thiazolidinedione (TZD)
pioglitazone has been shown to slow atherosclerosis in
T2DM patients as estimated by progression of maximal
carotid intima-media thickness [9] and coronary athero-
sclerosis [10] compared with glimepiride. Glucagon-like
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peptide (GLP)-1-based therapy, which includes dipeptidyl
peptidase (DPP)-4 inhibitors and GLP-1 receptor agonists,
has become a popular treatment for patients with T2DM.
The DPP-4 inhibitor sitagliptin has been speculated to
lower the prevalence of CVD [11]. However, recent large-
scale studies reported that, among patients with T2DM
who had experienced acute coronary syndrome recently,
the prevalence of major adverse cardiovascular events was
not increased or decreased with the DPP-4 inhibitors sax-
agliptin [12] or alogliptin [13], as compared with placebo
despite better control of HbA1c levels with both DPP-4
inhibitors than with placebo. Even if inconclusive, these
results suggest that some OHAs may have beneficial ef-
fects in reducing CVD events in individuals with T2DM.
The actual treatment goal of HbA1c by OHAs is recom-
mended to be 7.0 % (NGSP; National Glycohemoglobin
Standardization Program) for the prevention of diabetic
complication in Japan [14]. There are numerous difficulties
in assessment of the reduction of cardiovascular risk by
OHAs because a large volume of patient information must
be collected. Moreover, few reliable medical databases are
available in Japan, so data analyses are difficult. Conse-
quently, in Japan, there is little evidence regarding reduc-
tion in cardiovascular risk by OHAs. One way to solve this
problem may be to extract information from the National
Health Insurance program in Japan. This program offers
universal health coverage for all citizens (including compre-
hensive medical services and prescription medicines) and
covers >99 % of Japanese citizens.
Previously, we investigated the utility of this type of
multicenter medical-cost accounting database from
T2DM patients in 15 hospitals (Medical Data Vision
Co., Ltd. (MDV), Tokyo, Japan) by retrospective ana-
lyses. Statistical data of subjects showed an almost
identical tendency with that of Patient Survey 2008
conducted by the Ministry of Health, Labour and Wel-
fare in Japan (MHLWJ; estimated number of subjects
= 2,386,000), including the ratio of patients according
to sex, age distribution, and complications (e.g., dyslip-
idemia, hypertension). These findings suggested that
the MDV database could reflect the current situation
of T2DM in Japan [15]. Actually, the increased risk of
acute pancreatitis in patients with T2DM using the
MDV database has been reported recently [16]. In the
present study, we wanted to ascertain if differences in
reduction of the risk of CVD among various OHAs
could be observed using the MDV database.
Methods
Source of data
The study protocol was approved by the Review Board
on Clinical Research of Fukuoka University (Fukuoka,
Japan). This retrospective observational study was done
using a hospital-based composite database stored in
hospital electronic-information systems constructed by
MDV. MDV data were purchased by FUJIFILM Pharma
Co., Ltd. A contract between FUJIFILM Pharma Co., Ltd.,
and Fukuoka University Hospital enabled analyses to be
carried out. The current database of MDV has been ex-
panded to a much greater extent than that reported previ-
ously [15]. The database of the medical information of
patients (including laboratory data) was extracted from
the medical-cost accounting system of 103 institutions
(19 hospitals with <200 beds; 66 hospitals with 200–499
beds; and 18 hospitals with ≥500 beds) in Japan. This
database contains information about age, sex, diagnosis,
International Classification of Diseases (ICD)-10 code, sur-
gical history, outpatient/inpatient status, prescriptions, and
laboratory data. Written informed consent was not ob-
tained from each patient because all data were extracted
from the database retrospectively. Nevertheless, patient
anonymity was guaranteed.
Population
Two studies (study 1 and study 2) were undertaken. The
population of patients extracted in the present study sat-
isfied the following conditions: (i) began treatment with
a single OHA from 1 April 2008 to 30 April 2013; (ii)
HbA1c level (NGSP) at baseline was available; (iii) age at
baseline was 40–70 years; (iv) the presence or absence of
CVD history was not considered in study 1, but the
presence of CVD history was considered in study 2.
Exclusion criteria were: (i) began treatment with in-
sulin, GLP-1 analog, or compounding agent at base-
line; (ii) began treatment with ≥2 types of OHA; (iii)
admitted to hospital at baseline; (iv) an anti-cancer
drug was used before baseline measurements were
taken; (v) The patient who was judged having a missing
data by MDV Co., Ltd. The MDV database in 2013
contained the data of 225,197 individuals. Among
them, the baseline value of HbA1c was available for
29,074 patients. After careful adherence to inclusion
and exclusion criteria, 4095 and 1273 individuals were
subjected to cohort analyses of study 1 and study 2, re-
spectively. Outlines as well as the classification of in-
clusion and exclusion in study 1 and study 2 are
summarized in Figs. 1 and 2. Patients with cancer or liver
cirrhosis were not listed in any drug groups. However, renal
failure was noted in study 1: 2/629 (0.3 %) in the SU group,
4/1305 (0.3 %) in the BG group, 2/592 (0.3 %) in the α-GI
group, 2/351 (0.6 %) in the TZD group, 2/223 (0.9 %) in the
glinide group, and 6/995 (0.6 %) in the DPP-4 inhibitor
group. Renal failure was also noted in study 2: 1/228
(0.4 %) in the SU group, 0/325 (0 %) in the BG group,
0/203 (0 %) in the α-GI group, 1/140 (0.7 %) in the
TZD group, 2/70 (2.9 %) in the glinide group, and 6/
307 (2.0 %) in the DPP-4 inhibitor group. However,
there was no significant difference in the involvement
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of renal failure among the above 6 groups by Chi-
squared test, suggesting little impact on the analysis.
So we retained these data for the analysis.
Definition of a cardiovascular event
Information regarding cardiovascular events was obtained
from the MDV database. A cardiovascular event was de-
fined as suffering angina pectoris (codes I200, I201, I208
and I209), MI (I210–I213, I219, I220, I221 and I229),
heart failure (I500, I501 and I509), cerebral infarction
(I630–I635, I638 and I639), cerebral hemorrhage (I614
and I619), or subarachnoid hemorrhage (I600–I602, I604,
I605 and I609).
Follow-up study
Observation was stopped at the time of: (i) a cardiovascu-
lar event; (ii) changing of the OHA at baseline; (iii) discon-
tinuation of the drug at baseline before a prescription
period of 2 years. However, observation was not sus-
pended if a new OHA was added to the first drug. Finally,
1246 subjects and 412 cases in study 1 and study 2, re-
spectively, were treated continuously by a baseline drug
without a cardiovascular event being recorded for >2 years
(summarized in Figs. 1 and 2).
Data analyses
Baseline characteristics of patients (sex, age, HbA1c
level, use of other drugs (anti-hypertension or anti-
Fig. 1 Outline and flowchart of the protocol for patient selection for analyses of cardiovascular events in study 1
Fig. 2 Outline and flowchart of the protocol for patient selection for analyses of cardiovascular events in study 2
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dyslipidemia)) and cardiovascular events were analyzed.
Subjects were divided into six groups according to the
baseline drug. Prevalence of CVD and change in HbA1c
level from baseline in each drug group was assessed.
Statistical analyses
To verify the independence of the analysis in the present
study, statistical evaluation was undertaken by a specialist
organization (ING Corp., Tokyo, Japan). ING Corp., are in
no way associated with our institution or any drug com-
pany (including FUJIFILM Pharma Co., Ltd.). Statistical
analyses were done using SAS v9.1.3 for Windows (SAS In-
stitute, Cary, NC, USA). Prevalence of CVD in each group
was investigated by Kaplan-Meier analyses. Comparisons
between groups were achieved using the Cox-proportional
hazard model adjusted for sex, age, HbA1c level (NGSP),
use or non-use of anti-hypertensive drugs, and use or non-
use of anti-dyslipidemia drugs. For consideration of the
type-1 error in the Student’s t-test, patient characteris-
tics at baseline between two groups (SU vs BG, SU vs
α-GI, SU vs TZD, SU vs glinide, and SU vs DPP-4 in-
hibitor) were compared by the Dunnett test. P < 0.05
was considered significant.
Results
Validity of the database
The Japanese Patient Survey of 2011 for patients with
DM was published by the MHLWJ. Hence, we compared
our extracted database from 2013 with that of the
MHLWJ. Our database contained 225,197 subjects and
the percentage of males was 60.7 %. Based on data from
the MHLWJ, the estimated number of subjects with DM
in Japan was 2,700,000, and the percentage of males was
55.1 %. Age distribution of subjects with DM in our
database was 5.8 % in their forties, 13.8 % in their fifties,
28.6 % in their sixties, 29.9 % in their seventies, and
15.8 % in their eighties, whereas that for the MHLWJ
was 5.6, 13.7, 32.4, 31.1, and 13.4 %, respectively. The
percentage of males in our database was 71.5 % in their
forties, 68.7 % in their fifties, 65.6 % in their sixties,
60.2 % in their seventies, and 47.3 % in their eighties,
whereas that of MHLWJ was 68.2, 61.2, 57.8, 53.8 and
40.9 %, respectively. These results suggested that our
database could reflect the current situation of DM in
Japan, as reported previously.
Baseline characteristics of patients
Baseline characteristics of 4095 subjects in study 1 and
1273 subjects in study 2, including the six groups based
on the type of OHA (i.e., SU, biguanide, α-GI, TZD, gli-
nide, DPP-4 inhibitor) are shown in Tables 1 and 2, re-
spectively. Mean age of biguanide and TZD groups was
slightly (but significantly) younger than the SU group in
study 1 and study 2. Treatment with anti-hypertension
and anti-dyslipidemia drugs was undertaken in all OHA
groups. The detailed classification of antihypertensive
drugs and anti-dyslipidemia drugs used in subjects of
study 1 and 2 are shown in Additional files 1 and 2, re-
spectively. Mean HbA1c levels (NGSP) of biguanide, α-
GI, TZD and glinide were slightly (but significantly)
lower than those of the SU group in study 1 and study 2.
Prevalence of patients with a high HbA1c value (≥6.5 %)
was not significantly different between the SU group and
the other groups in study 1 and study 2. Mean duration
of administration of baseline drugs was 320–457 days in
study 1 and 330–540 days in study 2. In study 1, the
duration of administration of BG, α-GI, TZD and glinide
was not significantly different from that of SU, but that
of DPP-4 inhibitor was significantly shorter than that of
SU. In study 2, the duration of administration of BG was
significantly longer than that of SU, and that of DPP-4
inhibitor was significantly shorter than that of SU.
Prevalence of cardiovascular events in each group
Detailed data on the prevalence of cardiovascular events
in study 1 and study 2 are shown in Table 3A and B, re-
spectively. Based on these data, composite (cardiac and
cerebrovascular) cardiovascular events were used mainly
for statistical analyses subsequently because meaningful
values could not be obtained in the analysis of cerebral
events only due to the small number of events. The
number of cardiovascular events (1000 person-years) is
shown in Table 4A and B.
Kaplan-Meier curves for T2DM patients who experi-
enced ≥1 cardiovascular event in each group and statis-
tical comparisons between SU and other drugs in study
1 are shown in Fig. 3. For determination of the hazard
ratio (HR), the Cox proportional hazard model was ad-
justed for sex, age, HbA1c value (NGSP), use or non-use
of anti-hypertensive drugs, and use or non-use of anti-
dyslipidemia drugs. During a 104-week observation
period, patients who began treatment with BG showed a
significantly lower risk of cardiovascular events com-
pared with those who started treatment with SU. HR of
BG relative to SU was 0.603 (95 % confidence interval
[CI], 0.439–0.829, P = 0.002). Significant risk reduction
by BG relative to SU was also observed in analyses of
cardiac events only (HR, 0.613; 95 % CI, 0.438–0.857;
P = 0.004). However, α-GI, TZD, glinide and DPP-4 in-
hibitor did not show such significant reduction in risk
compared with SU in terms of cardiovascular events
and cardiac events (data not shown). A similar analysis
using Kaplan-Meier curves targeting T2DM patients who
did not have a history of cardiovascular events (n = 2822)
did not show a significant difference in the prevalence of
cardiovascular events between SU and other OHAs (data
not shown).
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Table 1 Clinical profiles of T2DM patients treated with oral hypoglycemic agents (OHAs) in study 1
SU BG α-GI TZD Glinide DPP-4 inhibitor
N = 629 N = 1305 P-value N = 592 P-value N = 351 P-value N = 223 P-value N = 995 P-value
Age 62 (60.8 ± 7.1) 59 (58.0 ± 7.9) <0.001 61 (60.1 ± 7.3) 0.38 60 (59.5 ± 7.2) 0.044 61 (60.4 ± 6.9) 0.95 62 (60.0 ± 7.6) 0.15
Male 454 (72.2) 823 (63.1) - 393 (66.4) - 236 (66.4) - 140 (62.8) - 634 (63.7) -
Anti-hypertensive agent
and anti-dyslipidemia agent
None 181 (28.8) 486 (37.2) - 176 (29.7) - 93 (26.5) - 79 (35.4) - 310 (31.2) -
Both of them 174 (27.7) 318 (24.4) - 212 (25.8) - 115 (32.8) - 51 (22.9) 302 (30.4) -
One of them 274 (43.6) 501 (38.4) - 204 (34.5) - 143 (40.7) - 93 (41.7) - 383 (38.5) -
HbA1c (NGSP %) 7.4 (7.9 ± 1.7) 7.2 (7.7 ± 1.6) 0.004 6.7 (6.9 ± 1.2) <0.001 6.7 (6.9 ± 1.2) <0.001 7.0 (7.1 ± 1.3) <0.001 7.4 (7.8 ± 1.5) 0.90
Minimum 4.7 5.0 4.9 5.1 4.6 5.1
Maximum 14.5 15.1 15.5 12.2 15 17.7
<6.5 % 100 (15.9) 216 (16.6) 224 (37.8) 125 (35.6) 60 (26.9) 89 (8.9)
- - - - -
6.5% ≤ 529 (84.1) 1089 (83.5) 369 (62.2) 226 (64.4) 163 (73.1) 906 (91.1)
Duration of administration
of baseline drug (days)
537 (457 ± 282) 612 (476 ± 278) 0.45 486 (453 ± 273) 1.00 521 (473 ± 249) 0.86 575 (499 ± 246) 0.16 281 (320 ± 241) <0.001













Table 2 Clinical profiles of T2DM patients treated with oral hypoglycemic agents (OHAs) in study 2
SU BG α-GI TZD Glinide DPP-4 inhibitor
N = 228 N = 325 P-value N = 203 P-value N = 140 P-value N = 70 P-value N = 307 P-value
Age 63.5 (62.4 ± 6.3) 61 (60.8 ± 6.7) 0.025 63 (61.3 ± 6.9) 0.27 62 (60.5 ± 6.7) 0.028 62 (61.1 ± 6.1) 0.50 63 (61.6 ± 6.8) 0.52
Male 183 (80.3) 206 (63.4) - 152 (74.9) - 101 (72.1) - 50 (71.4) - 216 (70.4) -
Anti-hypertensive agent and
anti-dyslipidemia agent
None 24 (10.5) 49 (15.1) - 21 (10.3) - 20 (14.3) - 11 (15.7) - 34 (11.1) -
Both of them 109 (47.8) 141 (43.4) - 126 (62.1) - 67 (47.9) - 30 (42.9) - 166 (54.1) -
One of them 95 (41.7) 135 (41.5) - 56 (27.6) - 53 (37.9) - 29 (41.4) - 107 (34.9) -
HbA1c (NGSP %) 7.3 (7.6 ± 1.5) 6.9 (7.1 ± 1.1) <0.001 6.6 (6.7 ± 1.0) <0.001 6.5 (6.8 ± 1.2) <0.001 6.9 (6.9 ± 0.9) <0.001 7.3 (7.6 ± 1.3) 0.97
Minimum 4.7 5.4 4.9 5.1 4.8 5.1
Maximum 14.1 14.4 11.4 11.8 9.4 13.7
<6.5% 44 (19.3) 78 (24.0) 87 (42.9) 62 (44.3) 21 (30.0) 29 (9.4)
- - - - -
6.5 % ≤ 184 (80.7) 24.7 (76.0) 116 (57.1) 78 (55.7) 49 (70.0) 278 (90.6)
Duration of administration
of baseline drug (days)
616 (477 ± 279) 730 (540 ± 261) 0.022 700 (510 ± 263) 0.56 596.5 (499 ± 251) 0.90 524.5 (485 ± 251) 1.00 302 (330 ± 245) <0.001













Kaplan-Meier curves for T2DM patients who had his-
tory of CVD events (study 2) revealed that the BG group
also significantly reduced the risk of cardiovascular
events relative to the SU group. The Cox proportional
hazard model was adjusted for sex, age, HbA1c value
(NGSP), use or non-use of anti-hypertensive drugs, and use
or non-use of anti-dyslipidemia drugs, and HR was deter-
mined to be 0.566 (95 % CI, 0.376–0.852, P = 0.006). How-
ever, a significant reduction in risk by BG relative to SU
was not observed if analyses were restricted to cardiac
events or stroke events (data not shown). With regard to all
other OHAs, significance was not observed in the risk
reduction of cardiovascular events, cardiac events, or stroke
events (data not shown).
Changes in HbA1c levels during the observation period
Changes in HbA1c levels from baseline (0 week) to
2 years (104 weeks) in patients in whom a cardiovascu-
lar event was observed were compared among OHAs.
In patients who began treatment with SU, BG, α-GI, a
TZD, glinide or DPP-4 inhibitor, the HbA1c level was
reduced with SU, BG, α-GI, a TZD and DPP-4 inhibi-
tor, but was increased with glinide. The maximum low-
ering effect in HbA1c level was observed in the DPP-4
Table 3 Number of cardiovascular events in subjects in study 1 (A) and study 2 (B)
OHAs (Administration of one medicine) Cardiovascular events (patients) Cardiac events (patients) Stroke (patients) Analysis
(A)
SU 80 71 10 629
Biguanide 84 76 10 1305
α-GI 63 58 7 592
TZD 35 29 6 351
Glinide 21 19 3 223
DPP-4 inhibitor 87 80 8 995
(B)
SU 58 53 6 228
Biguanide 47 48 4 325
α-GI 40 40 3 203
TZD 26 24 3 140
Glinide 14 14 1 70
DPP-4 inhibitor 56 57 3 307
Cardiovascular event: angina pectoris, myocardial infarction, heart failure, cerebral infarction, cerebral hemorrhage and subarachnoid hemorrhage
Cardiac event: angina pectoris, myocardial infarction and heart failure
Stroke event: cerebral infarction, cerebral hemorrhage and subarachnoid hemorrhage
Table 4 Number of cardiovascular events (1000 person-years) in subjects in study 1 (A) and study 2 (B)
N The number of cardiovascular events 1000 person-years
(A)
SU 629 80 108.9
BG 1305 84 51.0
α-GI 592 63 91.3
TZD 351 35 82.3
Glinide 223 21 71.2
DPP-4 inhibitor 995 87 105.2
(B)
SU 228 58 224.0
BG 325 47 106.2
α-GI 203 40 159.4
TZD 140 26 154.7
Glinide 70 14 162.1
DPP-4 inhibitor 307 56 222.7
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inhibitor group. The difference in the change in HbA1c
level between SU (−0.31 ± 0.07, N = 236) and glinide
(0.08 ± 0.12, N = 81), and between SU and DPP-4 inhibi-
tor (−0.75 ± 0.11, N = 95) was significant (P = 0.0005 and
P < 0.0001, respectively). However, the extent of change
in the level of BG (−0.30 ± 0.05, N = 542), α-GI (−0.21 ±
0.08, N = 195) and TZD (−0.31 ± 0.11, N = 92) relative to
that of SU was not significant (P = 0.90, P = 0.37 and P =
0.95, respectively). Similar results were observed in study 2.
The difference in the change in HbA1c level between SU
(−0.43 ± 0.11, N = 80) and TZD (−0.003 ± 0.16, N = 42) and
between SU and glinide (0.50 ± 0.20, N = 24) was significant
(P = 0.029 and P < 0.001, respectively). However, the extent
of change in the level of BG (−0.19 ± 0.08, N = 159), α-
GI (−0.19 ± 0.11, N = 80) and DPP-4 inhibitor (−0.27 ±
0.20, N = 27) relative to that of SU was not significant
(P = 0.069, P = 0.12 and P = 0.48, respectively).
Discussion
In the present study, T2DM patients who started treat-
ment with BG showed a significantly lower prevalence of
cardiovascular events compared with those who started
treatment with SU. This phenomenon was unrelated to
the presence or absence of CVD history.
Our results are based on a comparison of OHAs with
SU, and do not suggest that cardiovascular risk is re-
duced by BG but increased with SU. There were slight
differences in the backgrounds of patients in the six
OHA groups (e.g., slightly lower mean age and HbA1c
level in the BG group compared with the SU group). For
determination of the HR, the Cox proportional hazard
model was adjusted for sex, age, HbA1c value (NGSP),
use or non-use of anti-hypertensive drugs, and use or
non-use of anti-dyslipidemia drugs. As a result, 2-year
(104-week) observation of patients with T2DM (age,
40–70 years) who began treatment with a single OHA
revealed that BG significantly reduced the prevalence
of cardiovascular events compared with SU.
Meta-analyses focusing on the efficacy of BG for a re-
duction in cardiovascular risk have been reported [17].
In that report, metformin (a type of BG) reduced the in-
cidence of CVD compared with placebo/non-treated
subjects. Survival was also favorable in the metformin
group, but was reduced if metformin was administered
with SU. Another report made a direct comparison be-
tween BG and SU in which metformin reduced the inci-
dence of cardiovascular events and mortality [5]. The
results of the present study are in accordance with the
results of those reports. Compared with SU, BG has
been reported to have favorable effects on body weight,
lipid levels, and blood pressure [18]. BG has also been
reported to reduce the activity of plasminogen activator
inhibitor-1, which is a factor for thrombogenesis [19]
and exerts its protective effect against ischemia-reperfusion
injury after MI. These effects are considered not to be ex-
plained fully by the lowering effect of blood glucose [20].
Some SU drugs bind to the SUR2A/B receptor (located in
the myocardium and smooth muscle cells in coronary ar-
teries) and reduce the effect of ischemic preconditioning,
and possibly increase the risk of cardiovascular events [21].
Fig. 3 Kaplan-Meier curve for cardiovascular events during 104 weeks in patients with T2DM with or without a history of cardiovascular events.
Number of patients in each drug group is listed in Table 1. Numbers of those in which 104-week follow-up was completed were 629 in SU, 1305 in b
iguanide, 592 in α-GI, 351 in TZD, 223 in glinide, and 995 in DPP-4 inhibitor groups, respectively (Table 1). Numbers of those in which a cardiovascular event
was observed were 80 in SU, 84 in biguanide, 63 in α-GI, 35 in TZD, 21 in glinide, and 87 in DPP-4 inhibitor groups, respectively (Table 3A). Statistical
comparison of cardiovascular events during 104 weeks in patients with T2DM with a history of cardiovascular events is shown in the inserted small table.
Hazard ratio, Cox proportional hazard model adjusted by sex, age, HbA1c value (NGSP), use or non-use of anti-hypertensive drugs, use or
non-use of anti-dyslipidemia drugs. CI indicates a 95 % confidence interval. **P < 0.01
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Thus, the risk reduction of cardiovascular events by BG
relative to SU in the present study can be accounted for
(at least in part) by the mechanisms of action of BG and
SU stated above. Namely, a possibility of increased risk
of CV events by SU and a possibility of reduced risk of
CV evenyts by BG may result in our results.
In our analyses, the reduction in cardiovascular risk be-
tween drugs relative to SU was not associated with the re-
duction in HbA1c level. Several clinical trials, including
Action to Control Cardiovascular Risk in Diabetes
(ACCORD) [22], Action in Diabetes and Vascular Dis-
ease (ADVANCE) [23] and Veterans Affairs Diabetes
Trial (VADT) [24], have shown that intensive control
of glycemia does not consistently reduce the preva-
lence of cardiovascular events and, in some cases, may
be harmful. One reason for the failure in the reduction
in the prevalence of cardiovascular events is speculated
to be hypoglycemia [25]. Hypoglycemia is associated
with increased activation of the sympathetic nervous
system, which has been suggested to be a major risk
factor for adverse events [23]. Although not observed as
often as that seen with insulin, SU carries a relatively
greater risk of hypoglycemia [26]. This phenomenon may
explain (at least in part) the relative increase in the preva-
lence of cardiovascular events in the SU group compared
with BG groups even though a similar degree of reduction
in the HbA1c level was achieved.
Our study had several important limitations. First, des-
pite being a population-based study using a hospital
database, the sample size for analysis was not very large
because the inclusion and exclusion criteria of subjects
had to be considered. Second, this study was not a pro-
spective type of cohort analysis, making correct evalu-
ation of the clinical impact of each OHA very difficult.
Even though the first OHA was continued as the base-
line drug for ~1–1.4 years according to mean values, the
first OHA was sometimes switched to other OHAs, used
with other OHAs from certain time-points, or stopped
before 104 weeks. Third, the duration of follow-up (2 years)
may be relatively short for comparison of the prevalence of
cardiovascular events. Fourth, information of antihyperten-
sive drugs, antiplatelet or anticoagulant medications and
anti-dyslipidemia drugs which can affect CV outcomes,
were partly but not fully available from the database. We
could not completely rule out a possibility that these drugs
might have some impact on the CV outcome in this study.
In the present study, the effect of α-GI on reduction in
cardiovascular risk was not favorable compared with
that for SU, a result that is in contrast with other clinical
studies [7, 8]. α-GI might have had little impact on the
prevalence of cardiovascular events because of its rela-
tively lower level of HbA1c at the start of our study. The
vascular-protective effects of TZD or DPP-4 inhibitor
relative to SU was not demonstrated in our study despite
some favorable evidence in recent years [9–11, 27, 28],
though this topic remains controversial [12, 13]. DPP-4
inhibitors are effective and safe [29] and now expanding
the OHA market in Japan enormously, which will enable
this type of population-based analyses to be undertaken
again. Hence, the vascular-protective effect of OHAs (in-
cluding α-GI and DPP-4 inhibitor) seems to be inconclu-
sive and needs more careful interpretation in the
context of the limitations of our study. A slightly shorter
duration of administration of DPP-4 inhibitor relative to
SU in our study might have affected the results. Never-
theless, we can say with confidence that initial treatment
with BG and its baseline treatment for a certain period
of time could aid prevention of CVD events in T2DM
patients in Japan.
Despite the study limitations detailed above, our study
analyzing a database containing information on Japanese
individuals with T2DM in 103 hospitals revealed that
first treatment and baseline treatment for a certain dur-
ation with BG could significantly reduce the prevalence
of cardiovascular events compared with SU, and that this
effect was independent of its blood glucose-lowering ef-
fect. The American Diabetes Association and European
Association for the Study of Diabetes issued guidelines [30]
that incorporated information from clinical trials focusing
on cardiovascular outcomes [22–24]. Those guidelines rec-
ommend initial treatment with BG and emphasize a
patient-centric approach to treatment rather than adher-
ence to stricter control of glycemia [29]. BG does not have
strong glucose-lowering effects, but our findings will aid
the choice of anti-DM drugs for the prevention of cardio-
vascular events beyond glycemic control.
Conclusions
In Japanese subjects with T2DM, initial treatment and
baseline treatment with BG can reduce CVD risk relative
to that of SU, and this effect is independent of the blood
glucose-lowering effect of BG.
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